Liberate Bio Gains Licences for Myeloid-Specific CAR Design Patents

Why It Matters

The agreement fast‑tracks in vivo CAR‑M development, offering a potentially safer, more scalable alternative to CAR‑T and widening therapeutic options for oncology and autoimmune diseases. It also positions Liberate Bio to capture early market share in the emerging myeloid cell‑therapy segment.

Key Takeaways

• Licenses cover exclusive and non‑exclusive myeloid CAR patents
• Patents sourced from Carisma Therapeutics and University of Pennsylvania
• LNP platform enables in vivo programming of monocytes/macrophages
• Lead LNP achieved >99% B‑cell depletion in primates
• IND‑enabling studies target 2026 investigator‑initiated trial

Pulse Analysis

The rapid rise of chimeric antigen receptor (CAR) therapies has been dominated by T‑cell approaches, yet manufacturing complexity, cytokine release syndrome, and limited tissue penetration have spurred interest in alternative immune targets. Myeloid cells—monocytes and macrophages—offer distinct homing capabilities and innate immune functions, making them attractive vehicles for solid‑tumor and autoimmune interventions. In‑vivo CAR‑M strategies bypass ex‑vivo cell manipulation, potentially reducing cost, shortening timelines, and improving patient accessibility, while addressing safety concerns inherent to traditional CAR‑T.

Liberate Bio’s Raptor platform combines high‑throughput lipid nanoparticle (LNP) screening with patented myeloid‑specific CAR constructs licensed from Carisma Therapeutics and the University of Pennsylvania. The LNPs are engineered to home to extra‑hepatic immune cells, delivering genetic payloads that reprogram resident monocytes and macrophages directly within the body. Preclinical work demonstrated more than 99% depletion of circulating B cells in non‑human primates, a proof‑point of delivery efficiency and functional potency. With the newly acquired IP, the company is poised to file IND‑enabling studies and launch an investigator‑initiated trial by late 2026, marking a critical transition from discovery to clinical evaluation.

If successful, Liberate’s in‑vivo CAR‑M platform could reshape the cell‑therapy market by offering a scalable, off‑the‑shelf solution that mitigates many logistical hurdles of autologous CAR‑T. Investors are watching the space closely, as major biotech firms and pharmaceutical giants explore myeloid‑targeted modalities for both cancer and autoimmune indications. Regulatory pathways may also be more straightforward given the transient nature of LNP delivery compared with viral vectors. Ultimately, the licensing deal not only strengthens Liberate’s technical moat but also signals broader industry momentum toward next‑generation, immune‑reprogramming therapies.